-
Nov. 2021 – $6.8M Series B Financing
River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Adv
-
Apr. 2022 – Participation DCAT 2022
River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API
-
Jul. 2022 – Issuance of U.S. Patent
River Stone Biotech Inc. Announces Issuance of U.S. Patent . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive speci
-
Dec. 2023 – Global commercial launch
Advancing to global commercial launch . Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a dis
-
Jul. 2024 – Glycosylation of aloesone
Enzymatic glycosylation of aloesone performed by plant UDP-dependent glycosyltransferases . In a paper published in Glycobiology, researchers of the Danish
-
Mar. 2025 – Enzyme Discovery and In Vivo Assessment
Plant-Derived UDP-Glycosyltransferases for Glycosylation-Mediated Detoxification of Deoxynivalenol: Enzyme Discovery, Characterization, and In Vivo Resista
-
Oct. 2025 – Attending CPHI 2025
River Stone will be attending CPHI in Frankfurt next week – october 2025 . RSB is dedicated to providing life changing APIs and formulations via inno
-
Nov. 2025 – Production of nororipavine
Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource
-
Dec. 2025 – New US patent
River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 – New US